PremiumPre-EarningsSUPN Earnings this Week: How Will it Perform? Promising Growth Prospects for Supernus Pharmaceuticals: Buy Rating Driven by Qelbree and Onapgo Market Opportunities Serina Therapeutics initiated with a Buy at JonesResearch PremiumThe FlySupernus sees FY25 revenue $600M-$630M, consensus $622.27M Supernus Pharmaceuticals Updates Executive Compensation Packages SUPN Earnings Report this Week: Is It a Buy, Ahead of Earnings? PremiumThe FlySupernus announces FDA approval of ONAPGO Supernus announces U.S. FDA approved an update for label for Qelbree Supernus initiated with an Overweight at Cantor Fitzgerald